fda warning letters compounded semaglutide tirzepatide 2024 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about GLP-1 medications August 11, 2025: The FDA

Patients should continue their regular tirzepatide dosing schedule unless specifically instructed otherwise by their healthcare provider, but should avoid injecting into previously irritated areas

There was an increase in glutamine, taurine, glutathione, and xanthine in the tamoxifen-resistant compared to sensitive cells

We wanted to know whether their experience matched their expectations and what they wished theyd known before starting

Cohens d = 0.157

Just as a medication like Adderall must be tailored to the unique needs of each patient, so too must strategies for managing sleep problems in individuals with ADHD